264 related articles for article (PubMed ID: 15517230)
21. Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer.
Ławicki S; Głażewska EK; Sobolewska M; Będkowska GE; Szmitkowski M
Ann Lab Med; 2016 May; 36(3):223-9. PubMed ID: 26915610
[TBL] [Abstract][Full Text] [Related]
22. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
23. [Metalloproteinases (MMP-1, MMP-3) and their inhibitors (TIMP) in blood plasma of patients with prostate carcinoma].
Lein M; Nowak L; Jung K; Koenig F; Schnorr D; Loening SA
Urologe A; 1998 Jul; 37(4):377-81. PubMed ID: 9738289
[TBL] [Abstract][Full Text] [Related]
24. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
[TBL] [Abstract][Full Text] [Related]
25. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
[TBL] [Abstract][Full Text] [Related]
26. Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats.
Jung K; Krell HW; Ortel B; Hasan T; Römer A; Schnorr D; Loening SA; Lein M
Prostate; 2003 Feb; 54(3):206-11. PubMed ID: 12518325
[TBL] [Abstract][Full Text] [Related]
27. Plasma levels of E-cadherin and MMP-13 in prostate cancer patients: correlation with PSA, testosterone and pathological parameters.
Bonaldi CM; Azzalis LA; Junqueira VB; de Oliveira CG; Vilas Boas VA; Gáscon TM; Gehrke FS; Kuniyoshi RK; Alves BC; Fonseca FL
Tumori; 2015; 101(2):185-8. PubMed ID: 25733385
[TBL] [Abstract][Full Text] [Related]
28. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy.
Szarvas T; Becker M; Vom Dorp F; Meschede J; Scherag A; Bánkfalvi A; Reis H; Schmid KW; Romics I; Rübben H; Ergün S
Int J Cancer; 2011 Mar; 128(6):1486-92. PubMed ID: 20473942
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Role of Matrix Metalloproteinases 2, 7, 8, 9 and Their Type 1 Tissue Inhibitor in Blood Serum of Patients with Kidney Cancer.
Kushlinskii NE; Gershtein ES; Alferov AA; Bezhanova SD; Mushtenko VV; Pushkar DY; Matveev VB; Stilidi IS
Bull Exp Biol Med; 2020 Mar; 168(5):673-676. PubMed ID: 32248449
[TBL] [Abstract][Full Text] [Related]
30. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.
Miyake H; Nishikawa M; Tei H; Furukawa J; Harada K; Fujisawa M
Urol Oncol; 2014 Jul; 32(5):584-8. PubMed ID: 24680659
[TBL] [Abstract][Full Text] [Related]
31. Altered plasma matrix metalloproteinase-9/tissue inhibitor of matrix [corrected] metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer.
Kirman I; Jain S; Cekic V; Belizon A; Balik E; Sylla P; Arnell T; Forde KA; Whelan RL
Surg Endosc; 2006 Mar; 20(3):482-6. PubMed ID: 16432654
[TBL] [Abstract][Full Text] [Related]
32. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J
Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid.
Niimi Y; Pawankar R; Kawana S
Int Arch Allergy Immunol; 2006; 139(2):104-13. PubMed ID: 16374020
[TBL] [Abstract][Full Text] [Related]
34. Underexpression of MMP-2 and its regulators, TIMP2, MT1-MMP and IL-8, is associated with prostate cancer.
Reis ST; Antunes AA; Pontes-Junior J; Sousa-Canavez JM; Dall'Oglio MF; Piantino CB; Cruz JA; Morais DR; Srougi M; Leite KR
Int Braz J Urol; 2012; 38(2):167-74. PubMed ID: 22555040
[TBL] [Abstract][Full Text] [Related]
35. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
Salata IM; Stojanovic N; Cajdler-Łuba A; Lewandowski KC; Lewiński A
Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
[TBL] [Abstract][Full Text] [Related]
36. [Plasma matrix metalloproteinases MMP-2 and MMP-9 and tissue inhibitors TIMP-1 and TIMP-2 in children treated for acute lymphoblastic leukemia].
Krawczuk-Rybak M; Kuźmicz M; Mroczko B; Szmitkowski M
Pol Merkur Lekarski; 2010 Jul; 29(169):14-8. PubMed ID: 20712241
[TBL] [Abstract][Full Text] [Related]
37. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
[TBL] [Abstract][Full Text] [Related]
38. [Serum and urinary concentration of selected metalloproteinases and their tissue inhibitors in children with vesicoureteral reflux].
Taranta-Janusz K; Zoch-Zwierz W; Wasilewska A; Tenderenda E; Korzeniecka-Kozerska A
Pol Merkur Lekarski; 2010 Aug; 29(170):88-92. PubMed ID: 20842819
[TBL] [Abstract][Full Text] [Related]
39. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.
Incorvaia L; Badalamenti G; Rini G; Arcara C; Fricano S; Sferrazza C; Di Trapani D; Gebbia N; Leto G
Anticancer Res; 2007; 27(3B):1519-25. PubMed ID: 17595770
[TBL] [Abstract][Full Text] [Related]
40. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
